CHMP Recommends EU marketing authorisation of lanadelumab for prevention of HAE attack
Shire announced the EMA's Committee for Medicinal Products for Human Use adopted a positive opinion recommending the granting of marketing authorisation of lanadelumab injection for routine prevention of recurrent attacks of hereditary angioedema in patients aged 12 years and older. October 19, 2018